Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Annals of the New York Academy of Sciences
|
December 31, 2005
Morphogenics as a tool for target discovery and drug development
Nicholas C Nicolaides, Wolfgang Ebel, Brad Kline, et al.
Expert Opinion on Drug Discovery
|
March 16, 2013
Developing novel biopharmaceutical products through morphogenics
Nicholas C Nicolaides, Phillip M Sass, Qimin Chao, et al.
Plant Biotechnology Journal
|
December 19, 2006
Rapid generation of plant traits via regulation of DNA mismatch repair
Qimin Chao, Christine D Sullivan, John M Getz, et al.
Oncotarget
|
September 9, 2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
James Bradford Kline, Rina P Kennedy, Earl Albone, et al.
Journal of Immune Based Therapies and Vaccines
|
December 24, 2010
Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B
Brian Drozdowski, Yuhong Zhou, Brad Kline, et al.
Oncotarget
|
September 2, 2015
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
Katherine Rybinski, Hongxia Z Imtiyaz, Barrie Mittica, et al.
Cancer Immunity
|
March 10, 2007
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha
Wolfgang Ebel, Eric L Routhier, Brian Foley, et al.
Cancer Immunity
|
December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin
Raffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Cancer Biology & Therapy
|
September 13, 2013
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity
JianMin Lin, Jared L Spidel, Christopher J Maddage, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology
Jian Li, Tao Sai, Marc Berger, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Annals of the New York Academy of Sciences
|
December 31, 2005
Morphogenics as a tool for target discovery and drug development
Nicholas C Nicolaides, Wolfgang Ebel, Brad Kline, et al.
Expert Opinion on Drug Discovery
|
March 16, 2013
Developing novel biopharmaceutical products through morphogenics
Nicholas C Nicolaides, Phillip M Sass, Qimin Chao, et al.
Plant Biotechnology Journal
|
December 19, 2006
Rapid generation of plant traits via regulation of DNA mismatch repair
Qimin Chao, Christine D Sullivan, John M Getz, et al.
Oncotarget
|
September 9, 2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
James Bradford Kline, Rina P Kennedy, Earl Albone, et al.
Journal of Immune Based Therapies and Vaccines
|
December 24, 2010
Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B
Brian Drozdowski, Yuhong Zhou, Brad Kline, et al.
Oncotarget
|
September 2, 2015
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
Katherine Rybinski, Hongxia Z Imtiyaz, Barrie Mittica, et al.
Cancer Immunity
|
March 10, 2007
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha
Wolfgang Ebel, Eric L Routhier, Brian Foley, et al.
Cancer Immunity
|
December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin
Raffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Cancer Biology & Therapy
|
September 13, 2013
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity
JianMin Lin, Jared L Spidel, Christopher J Maddage, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 1, 2006
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology
Jian Li, Tao Sai, Marc Berger, et al.
Page
of 2